Vimarsana
Biggest News Aggregation in the World

Page 23 - Clinical Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Program Today - Breaking & Trending Today

Carson City foster home shortage at critical levels - Vimarsana News

Carson City foster home shortage at critical levels

The number of available foster homes in Carson City is so low right now that siblings cannot reside together in emergency foster care, a local panel of child welfare advocates said.

Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events - Vimarsana News

Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events

Aurinia Pharmaceuticals Inc. today announced that full results from the Phase 3, double-blind, placebo-controlled AURORA 2 extension study were published online in Arthritis & Rheumatology, the...

'Chemical cocktail' may reverse aging in just 1 week - Vimarsana News

'Chemical cocktail' may reverse aging in just 1 week

The “chemical cocktail” helped reverse aging in mice, but some experts are skeptical about whether it will work in humans.

Malibu compound that was once home to A-list rehab Promises hits market for $20M - but buyer will have to honor lease of existing treatment facility until it expires - Vimarsana News

Malibu compound that was once home to A-list rehab Promises hits market for $20M - but buyer will have to honor lease of existing treatment facility until it expires

A sprawling Malibu estate which once housed one of the world's best-known - and most expensive - rehab facilities has hit the market for $19.95 million.

Vivoryon Therapeutics N.V. Shares Clinical Development - Vimarsana News

Vivoryon Therapeutics N.V. Shares Clinical Development

Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s...